| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700178 | Clinical Oncology | 2009 | 7 Pages |
Abstract
VMAT is able to boost more of the CTV to â¥120% than cIMRT without contravening OAR dose constraints, and uses 48% fewer monitor units. Treatment times were 61% less than with cIMRT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. Shaffer, W.J. Morris, V. Moiseenko, M. Welsh, C. Crumley, S. Nakano, M. Schmuland, T. Pickles, K. Otto,